AMY SHELL: Open Payments
NPI 1750496253 · POPLAR BLUFF, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,115 in 59 payments from 20 companies in 2025. Trend: 2023 $564 · 2024 $957 · 2025 $1,115
Food & beverage: $1,038Education: $77
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $218 |
| Novo Nordisk Inc | 6 | $110 |
| Astellas Pharma US Inc | 2 | $93 |
| MAYNE PHARMA COMMERCIAL LLC | 5 | $86 |
| Axsome Therapeutics, Inc. | 3 | $78 |
| Boston Scientific Corporation | 2 | $61 |
| Sage Therapeutics, LLC | 3 | $61 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $56 |
| Lilly USA, LLC | 3 | $53 |
| Sumitomo Pharma America, Inc. | 2 | $49 |
Products named: UBRELVY, Auvelity, VRAYLAR, Axonics, ZURZUVAE, XIFAXAN, Ozempic, QULIPTA.
Industry payments across MO — which companies pay providers there.
